Median Technologies to Highlight AI Imaging Services at ASCO 2026
Event summary
- Median Technologies will showcase AI-powered imaging services for oncology clinical trials at ASCO 2026, May 29–June 2 in Chicago.
- The company will host two presentation sessions on radiopharmaceutical imaging and cachexia assessment.
- Antoine Iannessi, VP Medical Affairs iCRO, will lead the presentations.
- ASCO 2026 expects over 35,000 oncologists and industry stakeholders.
The big picture
Median Technologies is positioning itself as a key player in AI-driven oncology research, leveraging its presence at ASCO 2026 to showcase advancements in imaging services. The focus on radiopharmaceutical imaging and cachexia assessment aligns with the growing demand for precise, AI-enhanced diagnostic tools in clinical trials. The company’s ability to attract and retain biopharmaceutical partners will be critical to its long-term success in this competitive market.
What we're watching
- Market Adoption
- How quickly biopharmaceutical entities will integrate Median’s AI imaging services into their clinical trials.
- Regulatory Approval
- Whether the new solutions for radiopharmaceutical image processing and cachexia assessment will gain regulatory approval.
- Competitive Positioning
- The pace at which Median can differentiate itself from competitors in the AI-powered imaging services space.
Related topics